卒中后认知障碍(post-stroke cognitive impairment,PSCI)是脑卒中后常见的并发症,对患者的生活质量及生存时间构成极大的威胁。小胶质细胞是存在于中枢神经系统的主要免疫细胞,通过介导疾病的免疫反应发挥神经保护作用,在PSCI发病机制中发挥重要作用。研究表明,髓样细胞触发受体2(triggering receptor expressed on myeloid cells 2,TREM2),一种主要表达在小胶质细胞上的免疫反应受体,参与调控小胶质细胞的数量、吞噬、细胞因子释放和代谢功能。本文将 阐述TREM2调控小胶质细胞的活性对PSCI的影响,并探讨TREM2在PSCI治疗中的潜力。

Post-stroke cognitive impairment (PSCI) is a common complication following stroke, posing a significant threat to patients' quality of life and survival time. Microglia, the major immune cells in the central nervous system, play a crucial role in the pathogenesis of PSCI by mediating immune responses and exerting neuroprotective effects. Research has indicated that triggering receptor expressed on myeloid cells 2 (TREM2), an immune response receptor predominantly expressed on microglia, is involved in the regulation of microglial number, phagocytosis, cytokine release, and metabolic functions. In this article, we elucidate the effect of TREM2-mediated regulation of microglial activity on PSCI, and explore the potential of TREM2 as a therapeutic target for the prevention and treatment of PSCI.